Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

Palumbo, V.D., Romeo, M., Marino, A., Carini, F., Damiani, P., Damiano, G., et al. (2016). The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study. BIOMEDICAL PAPERS OF THE THE FACULTY OF MEDICINE OF PALACKÝ UNIVERSITY, OLOMOUC CZECH REPUBLIC, 160(3), 372-377 [10.5507/bp.2016.044].

The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

Palumbo, VD
;
Romeo, M.;Marino, A;Carini, F;Damiano, G;Buscemi, S;Lo Monte, AI;Tomasello, G
2016

Abstract

Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.
Settore MED/18 - Chirurgia Generale
Settore MED/12 - Gastroenterologia
Settore MED/07 - Microbiologia E Microbiologia Clinica
http://biomed.papers.upol.cz/doi/10.5507/bp.2016.044.pdf
Palumbo, V.D., Romeo, M., Marino, A., Carini, F., Damiani, P., Damiano, G., et al. (2016). The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study. BIOMEDICAL PAPERS OF THE THE FACULTY OF MEDICINE OF PALACKÝ UNIVERSITY, OLOMOUC CZECH REPUBLIC, 160(3), 372-377 [10.5507/bp.2016.044].
File in questo prodotto:
File Dimensione Formato  
The long-term effects of probiotics.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Versione Editoriale
Dimensione 97.73 kB
Formato Adobe PDF
97.73 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/202597
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 29
social impact